Compare Panacea Biotech with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PANACEA BIOTECH vs NOVARTIS - Comparison Results

PANACEA BIOTECH     Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PANACEA BIOTECH NOVARTIS PANACEA BIOTECH/
NOVARTIS
 
P/E (TTM) x 12.6 487.1 2.6% View Chart
P/BV x 3.0 28.3 10.7% View Chart
Dividend Yield % 0.0 1.6 -  

Financials

 PANACEA BIOTECH   NOVARTIS
EQUITY SHARE DATA
    PANACEA BIOTECH
Mar-18
NOVARTIS
Mar-18
PANACEA BIOTECH/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs364758 48.0%   
Low Rs129579 22.3%   
Sales per share (Unadj.) Rs96.8228.4 42.4%  
Earnings per share (Unadj.) Rs-12.431.7 -39.1%  
Cash flow per share (Unadj.) Rs-2.932.8 -8.7%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.5 0.0%  
Book value per share (Unadj.) Rs50.4297.1 17.0%  
Shares outstanding (eoy) m61.2524.69 248.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.52.9 87.0%   
Avg P/E ratio x-19.921.1 -94.3%  
P/CF ratio (eoy) x-86.420.4 -423.6%  
Price / Book Value ratio x4.92.2 217.4%  
Dividend payout %031.5 0.0%   
Avg Mkt Cap Rs m15,10116,505 91.5%   
No. of employees `0002.50.7 369.5%   
Total wages/salary Rs m1,5161,445 104.9%   
Avg. sales/employee Rs Th2,401.98,441.3 28.5%   
Avg. wages/employee Rs Th614.22,163.6 28.4%   
Avg. net profit/employee Rs Th-307.91,173.1 -26.3%   
INCOME DATA
Net Sales Rs m5,9285,639 105.1%  
Other income Rs m821,718 4.8%   
Total revenues Rs m6,0107,357 81.7%   
Gross profit Rs m845-63 -1,352.5%  
Depreciation Rs m58525 2,313.4%   
Interest Rs m1,00655 1,818.8%   
Profit before tax Rs m-6641,575 -42.1%   
Minority Interest Rs m00-   
Prior Period Items Rs m20-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m99792 12.5%   
Profit after tax Rs m-760784 -97.0%  
Gross profit margin %14.3-1.1 -1,286.5%  
Effective tax rate %-14.950.3 -29.6%   
Net profit margin %-12.813.9 -92.3%  
BALANCE SHEET DATA
Current assets Rs m5,6039,522 58.9%   
Current liabilities Rs m6,9103,296 209.7%   
Net working cap to sales %-22.0110.4 -20.0%  
Current ratio x0.82.9 28.1%  
Inventory Days Days20637 562.1%  
Debtors Days Days8428 294.6%  
Net fixed assets Rs m9,94146 21,610.3%   
Share capital Rs m61123 49.7%   
"Free" reserves Rs m3,0267,213 41.9%   
Net worth Rs m3,0877,336 42.1%   
Long term debt Rs m5,7070-   
Total assets Rs m16,07611,105 144.8%  
Interest coverage x0.329.5 1.2%   
Debt to equity ratio x1.80-  
Sales to assets ratio x0.40.5 72.6%   
Return on assets %1.57.6 20.2%  
Return on equity %-24.610.7 -230.5%  
Return on capital %3.922.2 17.6%  
Exports to sales %24.00-   
Imports to sales %17.50-   
Exports (fob) Rs m1,424NA-   
Imports (cif) Rs m1,040NA-   
Fx inflow Rs m1,60061 2,640.3%   
Fx outflow Rs m1,1313,630 31.2%   
Net fx Rs m469-3,570 -13.1%   
CASH FLOW
From Operations Rs m1,1801,610 73.3%  
From Investments Rs m553687 80.5%  
From Financial Activity Rs m-1,644-2,677 61.4%  
Net Cashflow Rs m90-380 -23.6%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 0.6 2.0 30.0%  
FIIs % 1.3 1.6 81.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 23.6 21.5 109.8%  
Shareholders   10,259 41,647 24.6%  
Pledged promoter(s) holding % 35.1 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PANACEA BIOTECH With:   CADILA HEALTHCARE  TTK HEALTHCARE  SHASUN PHARMA  DISHMAN PHARMA  J.B.CHEMICALS  

Compare PANACEA BIOTECH With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Strengthening Rupee, Inflation & Factory Output Data, and Top Stocks in Action Today(Pre-Open)

On Friday, Indian share markets witnessed most of the buying interest during closing hours and ended on a strong note.

Related Views on News

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

PANACEA BIOTECH 2017-18 Annual Report Analysis (Annual Result Update)

Mar 27, 2019 | Updated on Mar 27, 2019

Here's an analysis of the annual report of PANACEA BIOTECH for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of PANACEA BIOTECH. Also includes updates on the valuation of PANACEA BIOTECH.

PANACEA BIOTECH Announces Quarterly Results (3QFY19); Net Profit Down 137.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, PANACEA BIOTECH has posted a net profit of Rs 230 m (down 137.1% YoY). Sales on the other hand came in at Rs 1 bn (down 25.2% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

Buying these Eight Stocks is Like Owning Your Own Business(Profit Hunter)

Sep 5, 2019

Everyone dreams of owning a business. Here is your chance.

7 Stocks to Buy in the Market Today(The 5 Minute Wrapup)

Sep 5, 2019

The stock market had a four-year bull run starting September 2013. Are we seeing a similar pattern now?

Don't Buy Lakshmi Vilas Bank...Buy this Private Sector Bank with 74% Upside(The 5 Minute Wrapup)

Sep 4, 2019

Lakshmi Vilas Bank is in a vicious cycle. The stock is already down 57% in 2019. Despite this, the retail investors increased their holding.

Insider Buying Alert: Promoters Increase Stake in 8 High-Quality Smallcaps(Profit Hunter)

Sep 3, 2019

Insiders have increased their stakes in eight Hidden Treasure recommendations. Should you follow them?

Buy these 7 Stocks if You Believe in India(The 5 Minute Wrapup)

Sep 12, 2019

News headlines predict gloom and doom for India these days. You should ignore them.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

PANACEA BIOTECH SHARE PRICE


Sep 13, 2019 (Close)

TRACK PANACEA BIOTECH

  • Track your investment in PANACEA BIOTECH with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PANACEA BIOTECH

PANACEA BIOTECH 8-QTR ANALYSIS

COMPARE PANACEA BIOTECH WITH

MARKET STATS